In this Rare Perspectives roundtable discussion, our panelists will discuss the unique challenges that orphan drug developers face as they assess market potential and grapple with characterizing broad spectrums of disease, identifying targets and biomarkers, and raising disease awareness in the patient and clinical communities.
You’ll gain rare insights into:
• How rare disease companies decide which orphan drug programs to pursue
• How to foster stronger collaboration among drug developers, KOLs, patient advocates, and other stakeholders
• How we can work together to help end the diagnostic odyssey for rare disease patients
• A vision for the future of orphan drug development and patient advocacy
Speakers:
Alastair Garfield, PhD
Head of Translational Sciences and Strategy, Rectify Pharma
Samantha Parker, MBA
Chief Patient Access Officer, InnoSkel
Vice Chair, International Rare Disease Research Consortium, Chair
Mark Kiel, MD, PhD
CSO and Vice President of Product Strategy, Genomenon
Moderator
Lauren Chunn
Scientific Engagement Manager, Genomenon
Visit genomenon.com to learn more, or reach out to our team: hello@genomenon.com
